keyword
MENU ▼
Read by QxMD icon Read
search

apatinib

keyword
https://www.readbyqxmd.com/read/28061477/autocrine-vegf-signaling-promotes-cell-proliferation-through-a-plc-dependent-pathway-and-modulates-apatinib-treatment-efficacy-in-gastric-cancer
#1
Yi Lin, Ertao Zhai, Bing Liao, Lixia Xu, Xinhua Zhang, Sui Peng, Yulong He, Shirong Cai, Zhirong Zeng, Minhu Chen
BACKGROUND: Tumor cells produce vascular endothelial growth factor (VEGF) which interact with the membrane or cytoplasmic VEGF receptors (VEGFRs) to promote cell growth in an angiogenesis-independent fashion. Apatinib, a highly selective VEGFR2 inhibitor, is the only effective drug for patients with terminal gastric cancer (GC) who have no other chemotherapeutic options. However, its treatment efficacy is still controversy and the mechanism behind remains undetermined. In this study, we aimed to investigate the role of autocrine VEGF signaling in the growth of gastric cancer cells and the efficacy of Apatinib treatment...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28052652/anti-angiogenic-therapy-in-patients-with-advanced-gastric-and-gastroesophageal-junction-cancer-a-systematic-review
#2
Li-Tzong Chen, Do-Youn Oh, Min-Hee Ryu, Kun-Huei Yeh, Winnie Yeo, Roberto Carlesi, Rebecca Cheng, Jongseok Kim, Mauro Orlando, Yoon-Koo Kang
Despite advancements in therapy for advanced gastric and gastroesophageal junction cancers, their prognosis remains dismal. Tumor angiogenesis plays a key role in cancer growth and metastasis, and recent studies indicate that pharmacologic blockade of angiogenesis is a promising approach to therapy. In this systematic review, we summarize current literature on the clinical benefit of anti-angiogenic agents in advanced gastric cancer. We conducted a systematic search of PubMed and conference proceedings including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Cancer Congress...
January 3, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28028915/apatinib-in-gastric-carcinoma-a-case-report-of-partial-response-for-first-line-treatment-in-advanced-disease
#3
Yaping Wang, Minghong Bi, Haoran Zhang, Zhenyuan Gao, Hairong Zhou, Shu Chang
Gastric cancer (GC) is the most common gastrointestinal malignant tumor, with a gradual increasing incidence throughout the world. Mostly GC is diagnosed in its late stage. To date, there is no usable standardized treatment regimen for patients with advanced GC. Apatinib mesylate, small-molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI), has been approved as third-line treatment for patients with advanced gastric adenocarcinoma in China, October, 2014. Till now, there is no case report about apatinib as first-line treatment for patients with advanced GC in literature...
December 28, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27928929/angiogenesis-and-apatinib-a-new-hope-for-patients-with-advanced-gastric-cancer
#4
Ramon Andrade de Mello, Jailson de Oliveira, Georgios Antoniou
No abstract text is available yet for this article.
September 22, 2016: Future Oncology
https://www.readbyqxmd.com/read/27798730/cost-effectiveness-analysis-of-apatinib-treatment-for-chemotherapy-refractory-advanced-gastric-cancer
#5
Hong-Dou Chen, Jing Zhou, Feng Wen, Peng-Fei Zhang, Ke-Xun Zhou, Han-Rui Zheng, Yu Yang, Qiu Li
BACKGROUND: Apatinib, a third-line or later treatment for advanced gastric cancer (aGC), was shown to improve overall survival and progression-free survival (PFS) compared with placebo in the phase III trial. Given the modest benefit with high costs, we further evaluated the cost-effectiveness of apatinib for patients with chemotherapy-refractory aGC. METHODS: A Markov model was developed to simulate the disease process of aGC (PFS, progressive disease, and death) and estimate the incremental cost-effectiveness ratio (ICER) of apatinib to placebo...
October 31, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27793017/therapeutic-effect-of-apatinib-on-overall-survival-is-mediated-by-prolonged-progression-free-survival-in-advanced-gastric-cancer-patients
#6
Lihong Huang, Yongyue Wei, Sipeng Shen, Qianwen Shi, Jianling Bai, Jin Li, Shukui Qin, Hao Yu, Feng Chen
Apatinib is reported to significantly improve the overall survival (OS) of patients with advanced gastric cancer who have previously failed second-line chemotherapy. However, it is not well understood whether apatinib acts by improving progression or by prolonging post-progression survival. Here, based on phase III clinical trial data, the mediating effect of apatinib on patient overall survival was systematically quantified, through progression-free survival (PFS), post-progression survival (PPS), and the disease control rate (DCR)...
October 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27781258/-research-status-quo-and-progression-in-targeted-therapy-for-advanced-gastric-cancer
#7
Rui Feng, Xiaotian Zhang, Sheng Yang
With the deeper research of the proliferation, invasion and metastasis mechanisms of the gastric cancer, targeted therapy has become a hot spot in this field. The exploration of targeted agents for gastric cancer is mainly concentrated upon the drugs that target human epidermal growth factor receptor (HER) family, the vascular endothelial growth factor (VEGF), the phosphatidylinositol 3-kinase-protein kinase/mammalian target of rapamycin (PI3K/mTOR) and the NF-κB signaling pathways. The targeted drugs relevant to HER family include the Cetuximab, Nimotuzumab, Matuzumab, Panitumumab and Erlotinib which are aimed at HER-1, the Trastuzumab, Pertuzumab and T-DM1 (trastuzumab emtansine) which are aimed at HER-2, and the Lapatinib and Afatinib which are the multi-target agents of HER...
October 25, 2016: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/27738308/response-to-apatinib-in-chemotherapy-failed-advanced-spindle-cell-breast-carcinoma
#8
Na Zhou, Cong Min Liu, He Lei Hou, Chuan Tao Zhang, Dong Liu, Guan Qun Wang, Ke Wei Liu, Jing Juan Zhu, Hong Ying Lv, Tian Jun Li, Xiaochun Zhang
Spindle cell carcinoma of the breast is a rare subtype of metaplastic carcinoma, and no effective chemotherapy special for metaplastic carcinoma exists until now. As spindle cell carcinomas of the breast are typically "Triple Negative", endocrine therapy and molecular therapy targeted to Her2 might not be favorable, resulting in poor prognosis. Apatinib is currently being tested in patients with breast or lung cancers. Here we report a successful case using Apatinib to treat spindle cell carcinoma of breast...
October 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27631210/a-case-report-of-targeted-therapy-with-apatinib-in-a-patient-with-advanced-gastric-cancer-and-high-serum-level-of-alpha-fetoprotein
#9
Xue-Ru Zhu, Mei-Ling Zhu, Qing Wang, Wen-Ji Xue, Yi-Wei Wang, Rui-Fen Wang, Si-Yu Chen, Lei-Zhen Zheng
BACKGROUND: Alpha-fetoprotein (AFP) is an important marker for hepatocellular carcinoma, and the detection of serum AFP is currently the principle method for the diagnosis of hepatocellular carcinoma. The prevalence of gastric cancer (GC) with high level of serum AFP is extremely rare, but has unique clinical features. CASE SUMMARY: We herein present a rare case with GC and high level of serum AFP. A 64-year-old Chinese female underwent gastrectomy was diagnosed as gastric adenocarcinoma and the pathological stage was T1bN0M0, IA...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27568322/targeted-therapies-for-advanced-and-metastatic-adenocarcinoma-of-the-gastroesophageal-junction-is-there-something-new
#10
Felice Pasini, Anna Paola Fraccon, Yasmina Modena, Maria Bencivenga, Simone Giacopuzzi, Francesca La Russa, Milena Gusella, Giovanni de Manzoni
Despite improvements in systemic chemotherapy (CT), the prognosis of metastatic adenocarcinoma of the gastroesophageal junction remains poor. Over the years, new targeting agents have become available and were tested, with or without CT, in first or subsequent lines of therapy. The epidermal growth factor receptor family was targeted with monoclonal antibodies (MoAbs) (trastuzumab, cetuximab, panitumumab) and tyrosin kinase inhibitors (TKIs) (lapatinib, erlotinib, gefitinib). Only trastuzumab, in combination with cisplatin and fluoropyrimidines, significantly improved overall survival (OS) in first-line therapy (13...
August 27, 2016: Gastric Cancer
https://www.readbyqxmd.com/read/27563253/successful-treatment-of-angiosarcoma-of-the-scalp-with-apatinib-a-case-report
#11
Guanghui Ji, Liu Hong, Ping Yang
Angiosarcoma is a rare and aggressive vascular malignancy with a poor prognosis. There is no standard chemotherapy regime for advanced angiosarcoma. Here, we report a case of advanced angiosarcoma that was successfully treated with apatinib, an oral tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor-2 (VEGFR-2). To our knowledge, this is the first case to report the successful use of apatinib for angiosarcoma. Furthermore, the administration of apatinib results in fewer toxic effects than traditional cytotoxic chemotherapy...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27549930/3d-microtumors-in-vitro-supported-by-perfused-vascular-networks
#12
Agua Sobrino, Duc T T Phan, Rupsa Datta, Xiaolin Wang, Stephanie J Hachey, Mónica Romero-López, Enrico Gratton, Abraham P Lee, Steven C George, Christopher C W Hughes
There is a growing interest in developing microphysiological systems that can be used to model both normal and pathological human organs in vitro. This "organs-on-chips" approach aims to capture key structural and physiological characteristics of the target tissue. Here we describe in vitro vascularized microtumors (VMTs). This "tumor-on-a-chip" platform incorporates human tumor and stromal cells that grow in a 3D extracellular matrix and that depend for survival on nutrient delivery through living, perfused microvessels...
August 23, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27531538/gastric-cancer-clinical-and-epidemiological-aspects
#13
Marino Venerito, Alexander Link, Theodoros Rokkas, Peter Malfertheiner
Gastric cancer (GC) ranks fifth for cancer incidence and second for cancer deaths. Epidemiological data showed that survivors of Hodgkin's lymphoma and patients with pernicious anemia etiologically linked to autoimmune gastritis are at increased risk of GC. Screening of patients with autoimmune thyroid disease by means of pepsinogen (PG) I and PG I/II detected autoimmune gastritis with oxyntic gastric atrophy in one of four patients and may be recommended for GC prevention purposes. The International Agency for Research on Cancer reported a positive association between consumption of processed meet and increased GC risk...
September 2016: Helicobacter
https://www.readbyqxmd.com/read/27495042/significant-partial-response-of-metastatic-intra-abdominal-and-pelvic-round-cell-liposarcoma-to-a-small-molecule-vegfr-2-tyrosine-kinase-inhibitor-apatinib-a-case-report
#14
Min Dong, Jingwang Bi, Xiaohong Liu, Baocheng Wang, Jun Wang
INTRODUCTION: Myxoid/round cell liposarcoma is the second most common subtype of liposarcoma. Chemotherapy and radiotherapy have a limited efficacy for treating advanced myxoid/round cell liposarcoma, with relatively serious side effects. CASE PRESENTATION: We herein present a 68-year-old Chinese woman initially diagnosed with advanced multiple intra-abdominal and pelvic round cell liposarcoma.She refused to receive cytotoxic chemotherapy and received apatinib as the first-line therapy, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 that has been used in the treatment of patients with metastatic gastric cancer who progressed with 2 or more chemotherapy regimens...
August 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27494860/apatinib-inhibits-cellular-invasion-and-migration-by-fusion-kinase-kif5b-ret-via-suppressing-ret-src-signaling-pathway
#15
Chen Lin, Shanshan Wang, Weiwei Xie, Rongliang Zheng, Yu Gan, Jianhua Chang
The Rearranged during transfection (RET) fusion gene is a newly identified oncogenic mutation in non-small cell lung cancer (NSCLC). The aim of this study is to explore the biological functions of the gene in tumorigenesis and metastasis in RET gene fusion-driven preclinical models. We also investigate the anti-tumor activity of Apatinib, a potent inhibitor of VEGFR-2, PDGFR-β, c-Src and RET, in RET-rearranged lung adenocarcinoma, together with the mechanisms underlying. Our results suggested that KIF5B-RET fusion gene promoted cell invasion and migration, which were probably mediated through Src signaling pathway...
September 13, 2016: Oncotarget
https://www.readbyqxmd.com/read/27462154/therapeutic-effect-of-apatinib-loaded-nanoparticles-on-diabetes-induced-retinal-vascular-leakage
#16
Ji Hoon Jeong, Hong Khanh Nguyen, Jung Eun Lee, Wonhee Suh
Apatinib, a novel and selective inhibitor of vascular endothelial growth factor (VEGF) receptor 2, has been demonstrated recently to exhibit anticancer efficacy by inhibiting the VEGF signaling pathway. Given the importance of VEGF in retinal vascular leakage, the present study was designed to investigate whether apatinib-loaded polymeric nanoparticles inhibit VEGF-mediated retinal vascular hyperpermeability and block diabetes-induced retinal vascular leakage. For the delivery of water-insoluble apatinib, the drug was encapsulated in nanoparticles composed of human serum albumin (HSA)-conjugated polyethylene glycol (PEG)...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27417221/second-and-third-line-systemic-therapy-in-patients-with-advanced-esophagogastric-cancer-a-systematic-review-of-the-literature
#17
Emil Ter Veer, Nadia Haj Mohammad, Gert van Valkenhoef, Lok Lam Ngai, Rosa M A Mali, Martijn G H van Oijen, Hanneke W M van Laarhoven
The optimal second- and third-line chemotherapy and targeted therapy for patients with advanced esophagogastric cancer is still a matter of debate. Therefore, a literature search was carried out in Medline, EMBASE, CENTRAL, and oncology conferences until January 2016 for randomized controlled trials that compared second- or third-line therapy. We included 28 studies with 4810 patients. Second-line, single-agent taxane/irinotecan showed increased survival compared to best supportive care (BSC) (hazard ratio 0...
September 2016: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/27379402/population-pharmacokinetic-and-covariate-analysis-of-apatinib-an-oral-tyrosine-kinase-inhibitor-in-healthy-volunteers-and-patients-with-solid-tumors
#18
Mingming Yu, Zhiwei Gao, Xiaojian Dai, Hui Gong, Lianshan Zhang, Xiaoyan Chen, Da-Fang Zhong, Sherwin K B Sy
BACKGROUND AND OBJECTIVES: Apatinib is an oral tyrosine kinase inhibitor approved in China for the treatment of patients with advanced metastatic gastric cancer. The approved dosing schedule is 850 mg once daily. The objective of this study was to develop a population pharmacokinetic (popPK) model of apatinib and determine factors that affect its pharmacokinetics. METHODS: A popPK model for apatinib was developed using data from 106 individuals, including healthy volunteers and patients with malignant solid tumors...
July 5, 2016: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/27376400/apatinib-for-the-treatment-of-gastric-cancer
#19
Giandomenico Roviello, Andrea Ravelli, Anna Ida Fiaschi, Maria Rosa Cappelletti, Angela Gobbi, Chiara Senti, Laura Zanotti, Karol Polom, Andrew R Reynolds, Stephen B Fox, Daniele Generali
INTRODUCTION: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models. AREAS COVERED: Apatinib's efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer...
August 2016: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27306082/apatinib-in-metastatic-gastric-cancer-can-paclitaxel-make-the-difference
#20
Giandomenico Roviello, Franco Roviello, Karol Polom, Daniele Generali
No abstract text is available yet for this article.
September 2016: Anti-cancer Drugs
keyword
keyword
91338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"